Cargando…
Bumetanide As a Candidate Treatment for Behavioral Problems in Tuberous Sclerosis Complex
BACKGROUND: Recent studies indicate excitatory GABA action in and around tubers in patients with tuberous sclerosis complex (TSC). This may contribute to recurrent seizures and behavioral problems that may be treated by agents that enhance GABAergic transmission by influencing chloride regulation. C...
Autores principales: | Vlaskamp, Chantal, Poil, Simon-Shlomo, Jansen, Floor, Linkenkaer-Hansen, Klaus, Durston, Sarah, Oranje, Bob, Bruining, Hilgo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596068/ https://www.ncbi.nlm.nih.gov/pubmed/28943860 http://dx.doi.org/10.3389/fneur.2017.00469 |
Ejemplares similares
-
Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study
por: van Andel, Dorinde M., et al.
Publicado: (2020) -
Bumetanide Effects on Resting-State EEG in Tuberous Sclerosis Complex in Relation to Clinical Outcome: An Open-Label Study
por: Juarez-Martinez, Erika L., et al.
Publicado: (2022) -
Measurement of excitation-inhibition ratio in autism spectrum disorder using critical brain dynamics
por: Bruining, Hilgo, et al.
Publicado: (2020) -
Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol
por: Geertjens, Lisa, et al.
Publicado: (2022) -
Bumetanide for Irritability in Children With Sensory Processing Problems Across Neurodevelopmental Disorders: A Pilot Randomized Controlled Trial
por: van Andel, Dorinde M., et al.
Publicado: (2022)